EPIGENOMICS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 EUR | -11.17% |
|
-.--% | -62.96% |
| Apr. 30 | Epigenomics AG Announces Jens Ravens Leaves as Executive Board Member | CI |
| Mar. 14 | Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 63.61 | 59.42 | 20.03 | 7.841 | 6.958 | 1.613 |
| Enterprise Value (EV) 1 | 46.47 | 49.29 | 16.19 | -14.75 | -2.327 | 11.4 |
| P/E ratio | -3.76 x | -2.99 x | -1.68 x | -2.96 x | -0.57 x | -0.36 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 41.5 x | 52.8 x | 23.8 x | 1.26 x | 14.3 x | 4.75 x |
| EV / Revenue | 30.3 x | 43.8 x | 19.2 x | -2.38 x | -4.8 x | 33.6 x |
| EV / EBITDA | -3.53 x | -3.29 x | -1.62 x | 3.64 x | 0.19 x | -3.15 x |
| EV / FCF | -9.77 x | -6.21 x | -2.59 x | 7.26 x | 0.38 x | -4.6 x |
| FCF Yield | -10.2% | -16.1% | -38.6% | 13.8% | 263% | -21.7% |
| Price to Book | 3.42 x | 6.17 x | 5.18 x | 0.45 x | 0.68 x | -0.2 x |
| Nbr of stocks (in thousands) | 225 | 272 | 295 | 612 | 819 | 853 |
| Reference price 2 | 282.6 | 218.4 | 68.00 | 12.82 | 8.500 | 1.890 |
| Announcement Date | 3/27/19 | 4/29/20 | 3/12/21 | 3/1/22 | 4/25/23 | 3/14/24 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.533 | 1.125 | 0.842 | 6.203 | 0.485 | 0.3392 |
| EBITDA 1 | -13.15 | -14.97 | -10.01 | -4.057 | -12.45 | -3.614 |
| EBIT 1 | -13.29 | -15.1 | -10.11 | -4.162 | -12.86 | -4.177 |
| Operating Margin | -867.12% | -1,342.4% | -1,201.19% | -67.1% | -2,651.34% | -1,231.19% |
| Earnings before Tax (EBT) 1 | -13.43 | -14.57 | -11.66 | -2.41 | -12.1 | -4.464 |
| Net income 1 | -12.69 | -17.02 | -11.69 | -2.428 | -12.02 | -4.464 |
| Net margin | -827.92% | -1,512.89% | -1,387.89% | -39.14% | -2,479.18% | -1,315.79% |
| EPS 2 | -75.17 | -73.06 | -40.45 | -4.333 | -14.78 | -5.230 |
| Free Cash Flow 1 | -4.755 | -7.932 | -6.254 | -2.031 | -6.109 | -2.478 |
| FCF margin | -310.17% | -705.08% | -742.71% | -32.74% | -1,259.59% | -730.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/19 | 4/29/20 | 3/12/21 | 3/1/22 | 4/25/23 | 3/14/24 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 9.78 |
| Net Cash position 1 | 17.1 | 10.1 | 3.84 | 22.6 | 9.29 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -2.708 x |
| Free Cash Flow 1 | -4.75 | -7.93 | -6.25 | -2.03 | -6.11 | -2.48 |
| ROE (net income / shareholders' equity) | -87% | -121% | -173% | -18.7% | -74.5% | 72.4% |
| ROA (Net income/ Total Assets) | -39.9% | -52.7% | -60.8% | -16.5% | -39.7% | -19.5% |
| Assets 1 | 31.78 | 32.29 | 19.21 | 14.68 | 30.31 | 22.94 |
| Book Value Per Share 2 | 82.70 | 35.40 | 13.10 | 28.50 | 12.40 | -9.390 |
| Cash Flow per Share 2 | 73.20 | 37.30 | 12.10 | 29.70 | 12.40 | 2.470 |
| Capex 1 | 0.09 | 0.08 | 0.01 | 0.04 | 0.85 | 0 |
| Capex / Sales | 5.94% | 6.67% | 1.19% | 0.56% | 174.64% | 0.88% |
| Announcement Date | 3/27/19 | 4/29/20 | 3/12/21 | 3/1/22 | 4/25/23 | 3/14/24 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -62.96% | 667K | |
| -38.92% | 8.22B | |
| +1.92% | 3.52B | |
| -10.21% | 2.04B | |
| -29.79% | 1.82B | |
| -21.12% | 1.65B | |
| +12.21% | 928M | |
| +29.92% | 811M | |
| -7.42% | 702M | |
| -26.33% | 522M |
- Stock Market
- Equities
- ECX Stock
- Financials Epigenomics AG
